Methods and compositions for intra-nasal immunization with recombinant MVA encoding flagellin
AssigneeBavarian Nordic A/S
InventorsHenning Lauterbach, Hubertus Hochrein, Stephanie Sanos
Life of this patent
Estimating the term…
Abstract
Provided herein are immunogenic compositions comprising a recombinant modified vaccinia virus Ankara (MVA) comprising a nucleic acid sequence encoding a flagellin, and a nucleic acid sequence encoding a heterologous disease-associated antigen, wherein the immunogenic composition induces increased T-cell and antibody mediated immune responses specific for the heterologous disease-associated antigen when administered to a subject, e.g. a human subject, and related methods and uses.
Claims27
An immunogenic composition comprising a recombinant modified vaccinia virus Ankara (MVA) comprising a nucleic acid sequence encoding a flagellin and further comprising a nucleic acid sequence encoding a heterologous disease-associated antigen, wherein the immunogenic composition induces:
- a) increased T-cell and/or B-cell immune responses specific for the heterologous disease-associated antigen, and b) increased innate immune responses when administered to a subject as compared to T-cell and/or B-cell immune responses specific for the heterologous disease-associated antigen and innate immune responses induced by administration of a recombinant MVA comprising a nucleic acid sequence encoding a heterologous disease-associated antigen but not a nucleic acid sequence encoding a flagellin;
- wherein said recombinant modified vaccinia virus Ankara (MVA) is capable of reproductive replication in chicken embryo fibroblasts.
A method of inducing an antigen-specific immune response to a disease-associated antigen in a subject comprising administering to the subject an immunogenic composition comprising a nucleic acid sequence encoding a flagellin and further comprising a nucleic acid sequence encoding a heterologous disease-associated antigen, wherein the immunogenic composition induces:
- a) increased T-cell and/or B-cell immune responses specific for the heterologous disease-associated antigen, and b) increased innate immune responses as compared to T-cell and/or B-cell immune responses specific for the heterologous disease-associated antigen and innate immune responses induced by administration of a recombinant MVA comprising a nucleic acid sequence encoding a heterologous disease-associated antigen but not a nucleic acid sequence encoding a flagellin;
- wherein said recombinant modified vaccinia virus Ankara (MVA) is capable of reproductive replication in chicken embryo fibroblasts.
Dependencies are inferred from the claim text.